CLINICAL TRIALS PROFILE FOR PIRTOBRUTINIB

505(b)(2) Clinical Trials for PIRTOBRUTINIB

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT07350850 ↗	A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)	RECRUITING	China-Japan Union Hospital, Jilin University	PHASE2	2025-12-25	The goal of this clinical trial is to evaluate a new combination therapy for patients with newly diagnosed Primary Central Nervous System Lymphoma (PCNSL). The main questions it aims to answer are: (1) Does the combination of Methotrexate, Rituximab, Sintilimab, and Pirtobrutinib improve the Complete Remission Rate (CRR)? (2) Is this regimen safe and tolerable for patients? Researchers will compare this interventional group to a real-world observational group (receiving standard investigator-selected treatments) to see if the new combination improves treatment response and survival.
New Combination	NCT07350850 ↗	A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)	RECRUITING	First Affiliated Hospital of Fujian Medical University	PHASE2	2025-12-25	The goal of this clinical trial is to evaluate a new combination therapy for patients with newly diagnosed Primary Central Nervous System Lymphoma (PCNSL). The main questions it aims to answer are: (1) Does the combination of Methotrexate, Rituximab, Sintilimab, and Pirtobrutinib improve the Complete Remission Rate (CRR)? (2) Is this regimen safe and tolerable for patients? Researchers will compare this interventional group to a real-world observational group (receiving standard investigator-selected treatments) to see if the new combination improves treatment response and survival.
New Combination	NCT07350850 ↗	A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)	RECRUITING	Shanxi Provincial People's Hospital	PHASE2	2025-12-25	The goal of this clinical trial is to evaluate a new combination therapy for patients with newly diagnosed Primary Central Nervous System Lymphoma (PCNSL). The main questions it aims to answer are: (1) Does the combination of Methotrexate, Rituximab, Sintilimab, and Pirtobrutinib improve the Complete Remission Rate (CRR)? (2) Is this regimen safe and tolerable for patients? Researchers will compare this interventional group to a real-world observational group (receiving standard investigator-selected treatments) to see if the new combination improves treatment response and survival.

All Clinical Trials for PIRTOBRUTINIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04662255 ↗	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	Recruiting	Loxo Oncology, Inc.	Phase 3	2021-03-05	This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare LOXO-305 to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.
NCT04666038 ↗	Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL	Recruiting	Loxo Oncology, Inc.	Phase 3	2021-03-09	This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
NCT04849416 ↗	A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)	Recruiting	Eli Lilly and Company	Phase 2	2021-05-14	A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.

Clinical Trial Conditions for PIRTOBRUTINIB

Condition Name

Condition Name for PIRTOBRUTINIB
Intervention	Trials
Chronic Lymphocytic Leukemia	17
Small Lymphocytic Lymphoma	12
Healthy	12

Condition MeSH

Condition MeSH for PIRTOBRUTINIB
Intervention	Trials
Leukemia, Lymphocytic, Chronic, B-Cell	22
Lymphoma	13
Lymphoma, Mantle-Cell	12

Clinical Trial Locations for PIRTOBRUTINIB

Trials by Country

Trials by Country for PIRTOBRUTINIB
Location	Trials
United States	140
China	23
Japan	20
United Kingdom	12
Spain	11

Trials by US State

Trials by US State for PIRTOBRUTINIB
Location	Trials
Texas	18
Florida	16
New York	8
California	8
Massachusetts	7

Clinical Trial Progress for PIRTOBRUTINIB

Clinical Trial Phase

Clinical Trial Phase for PIRTOBRUTINIB
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	3
PHASE2	19

Clinical Trial Status

Clinical Trial Status for PIRTOBRUTINIB
Clinical Trial Phase	Trials
RECRUITING	25
Completed	11
Not yet recruiting	9

Clinical Trial Sponsors for PIRTOBRUTINIB

Sponsor Name

Sponsor Name for PIRTOBRUTINIB
Sponsor	Trials
Eli Lilly and Company	32
Loxo Oncology, Inc.	22
M.D. Anderson Cancer Center	6

Sponsor Type

Sponsor Type for PIRTOBRUTINIB
Sponsor	Trials
Industry	63
Other	29
NIH	2

Pirtobrutinib (Jaypirca) Clinical Trials Update and Market Outlook

Last updated: April 27, 2026

What is the latest clinical-trial picture for pirtobrutinib?

Pirtobrutinib is a next-generation, non-covalent BTK inhibitor used in B-cell malignancies, with the commercial product name Jaypirca (licensed in multiple geographies via prior-line and post-ibrutinib settings). The clinical development program is anchored in (1) label-expanding trials across B-cell lymphoma and CLL, and (2) phase 1/2 studies that define dose and combination strategy in earlier or higher-risk settings.

The current development posture is best interpreted through the trial types that are consistently active across BTK-resistant populations:

• Cohort-based phase 1/2 studies that establish safety and activity in patients with prior BTK inhibitor exposure and/or refractory disease.
• Randomized or controlled comparative trials that seek label expansion in distinct treatment lines or intent-to-treat populations.
• Combination trials that target complementary mechanisms (anti-CD20, PI3K, BCL2, or other pathway approaches) to deepen response depth and durability.

How is the evidence framing efficacy and safety across prior BTK exposure?

The clinical value proposition of pirtobrutinib rests on activity in populations with prior covalent BTK inhibitor treatment, where traditional resistance mechanisms reduce covalent inhibitor effectiveness. Across the program, endpoints focus on:

• Overall response rate (ORR) and duration of response (DoR)
• progression-free survival (PFS) in line-appropriate controlled settings
• overall survival (OS) as longer-horizon confirmation
• safety and tolerability with attention to class-relevant events (e.g., bleeding and atrial fibrillation) and class-differentiating tolerability profiles in continuous dosing schedules.

Across BTK inhibitor-exposed cohorts, the most decision-relevant readouts are ORR durability (DoR) and the event-free time profile (PFS), because both determine sequencing value versus other BTK inhibitors and chemoimmunotherapy strategies.

Which ongoing studies most drive label and competition outcomes?

Pirtobrutinib’s most material market drivers come from trials that:

• expand into earlier lines where BTK exposure history is lower,
• extend into specific lymphoma subtypes with unmet need,
• and validate combinations that improve response durability without unacceptable toxicity.

In business terms, the “next label” effect usually comes from one of three mechanisms: 1) a new line-of-therapy indication in CLL/SLL,
2) a new or broader lymphoma indication,
3) a subgroup claim that captures a distinct resistance pattern (e.g., BTK inhibitor-exposed, chemo-refractory, or high-risk molecular subsets).

What is the competitive market structure pirtobrutinib faces?

Pirtobrutinib competes in a BTK-inhibitor dominated landscape across CLL/SLL and B-cell lymphomas. The competitive set is determined less by mechanism class alone and more by sequencing advantages:

• Patients who receive covalent BTK inhibitors (acalabrutinib, ibrutinib, zanubrutinib) first generate a segment that later seeks a BTK strategy not dependent on the same covalent-binding mode.
• Pirtobrutinib’s differentiated positioning is strongest where prior BTK inhibitor exposure is common and outcomes are compromised.

From an investor and R&D standpoint, the competitive question is not “BTK vs BTK” in the abstract. It is whether pirtobrutinib:

• retains efficacy after covalent BTK inhibitor failure at clinically meaningful response duration,
• avoids clinically meaningful safety tradeoffs that shift use back to chemoimmunotherapy or alternative non-BTK regimens,
• and earns formulary preference through dosing convenience and toxicity management.

How do current dynamics translate into market projections?

Market projection for a prescription oncology asset like pirtobrutinib depends on three adoption levers: 1) indication breadth (how many lines and subtypes it covers), 2) eligible patient population growth (diagnosis incidence, survival, and sequencing practice), 3) share capture vs. covalent BTK inhibitors and non-BTK competitors (time-to-next-therapy driven by efficacy and safety).

For a BTK inhibitor, the principal adoption curve is shaped by:

• uptake in BTK-exposed disease (where the physician sees a clear rationale),
• and gradual expansion to earlier-line use if randomized evidence supports it.

Scenario framework for adoption (directional)

Because the trial pipeline can shift the label boundary, pirtobrutinib’s market path is typically modeled using three scenarios:

• Base case: label expansion modest but persistent, with strongest share in post-BTK settings.
• Upside case: clear evidence enables earlier-line penetration and/or broader lymphoma claims.
• Downside case: uptake remains concentrated in later lines due to comparative or safety/sequence friction.

A credible projection must explicitly map each scenario to the number of incremental indications and the speed of conversion from trial cohorts to real-world prescribing. The dominant driver is not early readouts alone; it is whether pivotal evidence creates guideline inclusion or payer coverage momentum.

What is the likely commercial trajectory by indication type?

A practical market segmentation for pirtobrutinib is:

• CLL/SLL and related high-risk CLL subsets: adoption hinges on comparative PFS/DoR and management of class-relevant safety issues in long-term administration.
• Mantle cell lymphoma (MCL) and other B-cell lymphomas: adoption hinges on response depth and durability after prior regimens, and the presence of BTK-exposed cohorts as a consistent market segment.
• Combination settings: adoption depends on whether combinations extend time-to-event without added toxicity or cost-of-therapy friction.

What are the key risks to the market outlook?

The highest-impact risks are operational and competitive:

• Sequencing resistance: if covalent BTK inhibitors retain use longer in front-line settings, it can compress the BTK-exposed segment size that benefits pirtobrutinib.
• Comparative efficacy in earlier lines: randomized data must show durable benefit without a safety or quality-of-life penalty.
• Competition from non-BTK regimens: chemo-free combination strategies and targeted agents can shift treatment patterns away from BTK inhibitors.
• Payer and formulary constraints: especially in earlier-line indications where treatment duration can be longer.

How does pirtobrutinib fit into payer and guideline decision-making?

Real-world uptake follows formulary logic:

• When a BTK-exposed population is clearly defined and response durability is supported, payers are more willing to cover.
• When claims require moving earlier in the line, payers demand stronger comparative endpoint readouts and robust subgroup performance.

The market winner effect in oncology is typically driven by the speed of guideline incorporation and formulary inclusion after label expansions supported by controlled evidence.

What operational levers determine whether projections land?

For R&D and business planning, pirtobrutinib’s market trajectory is most sensitive to:

• pivotal endpoint maturity (PFS and DoR strength in the targeted line),
• toxicity profile in real-world dosing (tolerability and discontinuation rates),
• combination tolerability (if used),
• and manufacturing capacity and supply reliability after adoption ramps.

Key Takeaways

• Pirtobrutinib’s clinical story is anchored in activity in BTK inhibitor-exposed B-cell malignancies and the program is structured around label expansion and combination strategies.
• The market outlook depends on how quickly randomized or comparative evidence broadens indications beyond post-BTK settings and whether that evidence converts into guideline and payer adoption.
• The strongest adoption segment is the post-covalent BTK-exposure population; earlier-line penetration requires controlled efficacy and durable time-to-event outcomes without new safety burdens.
• The largest risks are sequencing compression and stronger-than-expected competitive pull from non-BTK regimens and from covalent BTK inhibitors in earlier lines.

FAQs

1) What is pirtobrutinib’s primary market differentiator?

Its non-covalent BTK inhibition positions it for use after covalent BTK inhibitor exposure, where resistance can reduce outcomes with covalent agents.

2) What endpoints matter most for adoption?

PFS and DoR for the relevant line of therapy drive formulary and guideline uptake more directly than early ORR alone.

3) Which development activity is most tied to revenue expansion?

Trials that expand indications into earlier lines or additional lymphoma subtypes, especially those with controlled evidence supporting durable benefit.

4) How do safety and tolerability affect sales velocity?

Long-term tolerability determines persistence and physician willingness to choose the drug for earlier-line use, where dosing duration is longer.

5) What is the biggest competitive threat to pirtobrutinib’s projected growth?

Earlier-line treatment shifts toward non-BTK combinations or sustained use of covalent BTK inhibitors if comparative benefits do not sufficiently outweigh sequencing and toxicity tradeoffs.

---

References

[1] U.S. Food and Drug Administration. “FDA approves Jaypirca for mantle cell lymphoma.” FDA News Release.
[2] European Medicines Agency. “Jaypirca (pirtobrutinib) EPAR.” EMA.
[3] ClinicalTrials.gov. “Pirtobrutinib (LOXO-305).” NCT listings and study statuses.